CXCR4 and neoplasm: Treatment with AMD3100 in combination with anti-PD-L1 led to a significant reduction in tumor growth.436 Moreover, in a mouse model of human prostate carcinoma, combining docetaxel with AMD3100 showed a superior antitumor effect compared to docetaxel alone, suggesting that CXCR4 inhibition can effectively chemo-sensitize prostate cancer cells.